Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of February 2021, with a filing date of February 17, 2021. The document serves as a notice regarding corporate governance activities rather than a financial report.
Key Corporate Action
The Company has scheduled an Extraordinary Meeting of Shareholders for March 31, 2021, at 4:00 p.m. Israel time. The meeting will be held at the offices of Gross & Co. in Tel Aviv, Israel.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document contains no financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing. The primary change is the scheduling of a shareholder meeting.
Outlook and Management Commentary
Management commentary is limited to the logistical details of the upcoming shareholder meeting. The Notice of Extraordinary Meeting of Shareholders is included as Exhibit 99.1 and incorporated by reference into the Company's Registration Statements on Form F-3 and Form S-8. No specific guidance, risks, or contingencies are detailed in the body of this report.
Investor Verification Checklist
- Verify the specific agenda items for the Extraordinary Meeting of Shareholders scheduled for March 31, 2021, by reviewing Exhibit 99.1.
- Confirm the Company's name is BiondVax Pharmaceuticals Ltd., as the input metadata referenced Scinai Immunotherapeutics Ltd.
- Check the referenced Registration Statements (Form F-3 No. 333-240189 and Form S-8 No. 333-239344) for details on the matters to be voted upon.